- Trials with a EudraCT protocol (28,934)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28,934 result(s) found for: Informed consent.
Displaying page 9 of 1,447.
EudraCT Number: 2008-008012-98 | Sponsor Protocol Number: sl2008-1 | Start Date*: 2009-12-18 |
Sponsor Name:Stefan Lundeberg | ||
Full Title: Pharmacokinetic study of the opioid ketobemidone in neonates after an intravenous administration | ||
Medical condition: Pain treatment with opioids in children | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006717-32 | Sponsor Protocol Number: 554 | Start Date*: 2007-01-31 |
Sponsor Name:Stefan Lundeberg | ||
Full Title: Pharmacokinetic study of the opioid ketobemidone in children and adolescens after intravenous administration | ||
Medical condition: Pain treatment with opioids in children | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002030-37 | Sponsor Protocol Number: A7281009 | Start Date*: 2013-01-08 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS ... | ||||||||||||||||||
Medical condition: Crohn’s Disease (CD) and Ulcerative Colitis (UC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) NL (Completed) IT (Completed) PL (Completed) SK (Completed) HU (Completed) CZ (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) BG (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000331-63 | Sponsor Protocol Number: HGB-210 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name: bluebird bio, Inc. | |||||||||||||
Full Title: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease. | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002101-39 | Sponsor Protocol Number: MD7111396 | Start Date*: 2008-09-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration | |||||||||||||
Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001110-38 | Sponsor Protocol Number: TOCIVID-19 | Start Date*: 2020-03-18 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE" | |||||||||||||
Full Title: Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia | |||||||||||||
Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002569-37 | Sponsor Protocol Number: APHP180584 | Start Date*: 2020-05-13 |
Sponsor Name:Assistance Publique Hôpitaux de Paris | ||
Full Title: Empirical steroids and/or antifungals in immunocompromised patients with acute respiratory failure from undetermined etiology: a multicenter double-blind randomized controlled trial | ||
Medical condition: immunocompromised patients with acute respiratory failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002646-36 | Sponsor Protocol Number: B1481022 | Start Date*: 2014-02-14 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017 | |||||||||||||
Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M... | |||||||||||||
Medical condition: atherosclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) SE (Completed) SK (Prematurely Ended) ES (Completed) IT (Completed) BE (Prematurely Ended) DK (Completed) PL (Prematurely Ended) IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000900-41 | Sponsor Protocol Number: WB28850 | Start Date*: 2013-05-10 |
Sponsor Name:F. Hoffmann-La Roche, Ltd. | ||
Full Title: A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA | ||
Medical condition: Severe corticosteroid-dependent asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004095-37 | Sponsor Protocol Number: CQAB149A2222 | Start Date*: 2005-02-25 |
Sponsor Name:Novartis Pharma Services | ||
Full Title: An exploratory, multi-center, randomized, open-label, single dose, crossover study to assess the safety and tolerability of 200µg of QAB149, delivered via a MDDPI, with or without the co-administra... | ||
Medical condition: 1) Stable persistent asthma 2) COPD | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) BE (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003811-36 | Sponsor Protocol Number: 107012 | Start Date*: 2007-01-03 |
Sponsor Name:NV Organon | ||
Full Title: A phase III, randomized, double-blind, active-controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 µg Org 36286 (corifollitropin alfa) to induc... | ||
Medical condition: Controlled Ovarian Stimulation (COS) to induce the development of multiple follicles in patients participating in an Assisted Reproductive Technology (ART) program | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) AT (Completed) DK (Completed) CZ (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003512-40 | Sponsor Protocol Number: 20150120 | Start Date*: 2018-03-05 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Heal... | |||||||||||||
Medical condition: Postmenopausal osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000851-11 | Sponsor Protocol Number: W00118CR401 | Start Date*: 2020-10-30 |
Sponsor Name:Pierre Fabre Dermatologie | ||
Full Title: Frequency and Intensity of local reactions in patients treated with 4% 5-FU vs 4% 5-FU associated with an emollient cream: a randomised, controlled clinical trial | ||
Medical condition: Actinic keratosis with 5 or more clinically recognizable (palpable and/or visible to unaided eye) AK lesions of the face, and/or ears and/or scalp. The lesions must be clinically typical non hypert... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002648-10 | Sponsor Protocol Number: ADDI-D | Start Date*: 2014-03-04 |
Sponsor Name:Bruno Farmaceutici S.p.a. | ||
Full Title: THE EFFECT OF A DAILY AND WEEKLY ADMINISTRATION OF DIFFERENT DOSES OF CALCIDIOL ON 25(OH)D3 SERUM LEVELS AND ON MINERAL AND BONE METABOLIC MARKERS IN POSTMENOPAUSAL FEMALE SUBJECTS OVER 55 YEARS OF... | ||
Medical condition: Postmenopausal female subjects with inadequate levels or deficit of 25(OH)D3 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002640-97 | Sponsor Protocol Number: A6121128 | Start Date*: 2004-10-27 |
Sponsor Name:Pfizer | ||
Full Title: Time to onset of action of tolterodine using force fill cystometry in SPINAL CORD INJURY PATIENTS WITH neurogenic detrusor overactivity. | ||
Medical condition: Neurogenic detrusor overactivity in patients with spinal cord injury | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000376-28 | Sponsor Protocol Number: 1245.148 | Start Date*: 2018-01-30 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients w... | |||||||||||||
Medical condition: Chronic heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF) diagnosed at least 3 months prior to informed consent. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015525-37 | Sponsor Protocol Number: D1950C00006 | Start Date*: 2010-01-27 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: Safety, Tolerability and Pharmacokinetics of 3 Dose regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo controlled, Parallel group... | |||||||||||||
Medical condition: Patients with mild to moderate Alzheimer's Desease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003616-20 | Sponsor Protocol Number: MK1439A-030 | Start Date*: 2015-12-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhi... | |||||||||||||
Medical condition: Human Immunodeficiency Virus-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004255-70 | Sponsor Protocol Number: 205687 | Start Date*: 2017-05-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasa... | |||||||||||||
Medical condition: Treatment of nasal polyposis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005035-19 | Sponsor Protocol Number: A3921024 | Start Date*: 2007-04-17 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB (CP-690,550) FOR TREATMENT OF RHEUMATOID ARTHRITIS | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) AT (Completed) SE (Completed) IT (Completed) HU (Completed) CZ (Completed) GR (Completed) DE (Completed) SK (Completed) GB (Completed) BG (Completed) FI (Completed) DK (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
